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  1ABSTRACT 
 
 
Objective: To estimate the effect of differential cost sharing (DCS) schemes for non-steroidal 
anti-inflammatory drugs (NSAIDs) on drug subsidy program and beneficiary expenditures. 
Data Sources/Study Setting: Monthly aggregate claims data from Pharmacare, the public drug 
subsidy program for seniors in British Columbia, Canada over the period 1989-11 to 2001-06. 
Study Design: DCS limits insurance reimbursement of a group of therapeutically similar drugs 
to the cost of the lowest priced drugs, with beneficiaries responsible for costs above the 
reimbursement limit.  Pharmacare introduced two different forms of DCS, generic substitution 
(GS) and reference pricing (RP), in April 1994 and November 1995, respectively, to the 
NSAIDs.  Under GS, generic and brand versions of the same NSAID are considered 
interchangeable, whereas under RP different NSAIDs are.  We extrapolated average 
reimbursement per day of NSAID therapy over the months before GS and RP to estimate what 
expenditures would have been without the policies.  These counterfactual predictions were 
compared to actual values to estimate the impact of the policies; the estimated impacts on 
reimbursement rates were multiplied by the post-policy volume of NSAIDS dispensed, which 
appeared unaffected by the policies, to estimate expenditure changes.   
Data Collection: The cleaned NSAID claims data, obtained from Pharmacare’s databases, were 
aggregated by month and by their reimbursement status under the GS and RP policies. 
Principal Findings: After RP, program expenditures declined by $22.7 million, or $4 million 
annually, cutting expenditure by half.  Most savings accrued from the substitution of low cost 
NSAIDs for more costly alternatives.  About 20% of savings represented expenditures by seniors 
who elected to pay for partially-reimbursed drugs.  GS produced one quarter the savings of RP. 
Conclusions: RP of NSAIDs achieved its goal of reducing drug expenditures and was more 
effective than GS.  The effects of RP on patient health and associated health care costs remain to 
be investigated. 
Key Words: Reference pricing; generic substitution; prescription drugs; drug cost containment 
NSAIDs.  
  2 
Introduction 
 
Differential cost sharing has been used by both public and private drug insurance 
programs to limit program expenditures.  Under this scheme, reimbursement of each drug in a 
group of ‘therapeutically similar’ drugs is limited to an average of the prices of the lowest cost 
drugs in the group.  Patients wanting higher cost drugs are responsible for the difference in drug 
price and the reimbursement limit.  Differential cost sharing programs come in two basic flavors, 
depending on the drugs considered therapeutically similar: (1) different brands of chemically 
equivalent drugs and (2) chemically distinct but therapeutically related drugs.  The former flavor, 
often referred to as generic substitution (GS), is widely used, whereas the latter, known as 
reference pricing (RP), has been used less frequently and is controversial, although evidence on 
its effects is beginning to emerge (Lopez-Casasnovas and Puig-Junoy 2000; Grootendorst et al. 
2001a; Schneeweiss 2002a;  Schneeweiss 2002b; Hazlet and Blough 2002).  Some have 
recommended that RP be integrated into the Medicare prescription drug benefit (Huskamp et al. 
2000; Morgan, Barer, and Agnew 2003).  In this paper, we compare the drug program savings 
realized by the application of GS and RP to the class of non-steroidal anti-inflammatory drugs 
(NSAIDs) by Pharmacare, the publicly funded drug subsidy program for seniors, welfare 
recipients and other residents of British Columbia (BC), Canada.   
Given that there is more price variation between different NSAIDs than there is between 
different brands of the same NSAID, RP should produce greater budgetary savings than GS.  As 
an example, an academic research group, the BC Therapeutics Initiative, reported in 1995 that 
the daily cost of acetylsalicylic acid (ASA) varied between $0.06 to $0.17 (depending on the 
amount used), whereas the daily cost of a newer NSAID, etodolac, varied from $1.79 to $3.58 
  3(Therapeutics Initiative 1995). Critics contend, however, that RP cannot control drug costs in the 
longer term, for several reasons.  First, physicians can apply for exemption from RP for 
Pharmacare beneficiaries that have failed or are likely to fail on a lower cost, fully reimbursed 
drug.  Although they require paper work, exemption requests are usually granted.  Second, 
physicians might substitute relatively costly analgesics that are not subject to RP (such as 
oxycodone) for those that are.  Third, economic theory suggests that setting reimbursement rates 
according to the prices of a set of reference standard drugs might encourage the manufacturers of 
those drugs to raise prices. (Morton 1997; Zwefel and Crivelli 1996; Anis and Wen 1998)  
Finally, although Pharmacare saves money on those beneficiaries who elect to pay extra for the 
higher cost drugs, these expenditures are merely shifted – overall drug costs do not decline.   
  To address these issues, we used aggregated monthly Pharmacare claims data to examine 
Pharmacare reimbursement rates for NSAIDs, as well as prescribing patterns and Pharmacare-
reimbursed expenditures for NSAIDs and other analgesic drugs and patients’ out-of-pocket 




Pharmacare NSAID reimbursement policies 
In addition to GS and RP, Pharmacare introduced several other policies during the 1990s 
to limit NSAID expenditures.  The first of these was the delisting of selected sustained release 
(SR) NSAIDs in January 1993 from the formulary.  This was followed by the April 1994 
introduction of GS, under the auspices of the Low Cost Alternative (LCA) program.  LCA 
limited Pharmacare reimbursement of multi-sourced drugs (i.e. different brands of drugs with the 
  4same active ingredient, dosage form and strength) to the average of the lowest cost (typically 
‘generic’) drugs.  RP was introduced in November 1995.  Under the policy, the less costly 
‘Unrestricted’ NSAIDs, enteric coated ASA (650mg), ibuprofen and naproxen remained fully 
reimbursed; Pharmacare also began to reimburse acetaminophen (500mg).  The decision to 
provide full reimbursement for acetaminophen, ASA, ibuprofen and naproxen was consistent 
with earlier recommendations by the BC Therapeutics Initiative that these drugs be used as first 
line therapy for osteoarthritis (Therapeutics Initiative 1995).   
Reimbursement of the ‘First Line Restricted’ NSAIDs (diclofenac, 
diclofenac/misoprostol (Arthrotec), diflunisal, fenoprofen, flurbiprofen, indomethacin, 
ketoprofen, naproxen SR and enteric coated tablets, and salsalate) was initially limited to 
$0.45/day ($13.45 for a 30 day supply), then reduced to $0.43/day on March 1, 2001.  Patients 
intolerant of Unrestricted NSAIDS or with specific diagnoses (rheumatoid arthritis, psoriatic 
arthritis, ankylosing spondylitis, collagen vascular disease or gout) were eligible for exemption 
from the policy.  Exemption required that physicians submit a written request to a Pharmacare 
pharmacist, who would then adjudicate the request and render a decision, typically within 48 
hours.  All NSAID prescriptions written by rheumatologists were automatically exempted from 
RP.  Exemption for a ‘Second Line Restricted’ NSAID (nabumetone, piroxicam, tenoxicam, 
tiaprofenic acid, tolmetin, sulindac, ketorolac or diclofenac potassium) required failure on a First 
Line Restricted NSAID.  These Second Line drugs were delisted a year later (November 1996), 
but concerns expressed by physicians and pharmacists led to reinstatement of all but ketorolac 
and diclofenac potassium under the ‘Special Authority’ program in February 1997.  Special 
Authority, also known as ‘prior authorization’, is similar to RP in that Pharmacare will fully 
  5reimburse a drug only if it approves.  Special Authority differs from RP in that Pharmacare will 
not reimburse any of the cost of targeted drugs for patients who fail to receive prior approval. 
Various other NSAIDs
1 were either delisted or required special authority at various times 
over the sample period, but these drugs collectively accounted for less than 7% of all NSAID 
prescribing in the 19 months before RP.  Notably, the cyclooxygenase-2 selective inhibitors 
(COX-2s) were also placed under special authority at the time of their introduction in September 
2000.  We assessed these drugs separately because they were reimbursed by Pharmacare only 
late into our sample period. 
 
Data 
BC Pharmacare provided monthly prescribing and expenditures data on individual 
NSAIDs and other analgesics, for its senior (age 65+) beneficiaries for the period November 
1989 to June 2001.  A previous report indicated high accuracy and completeness of provincial 
government drug claims data. (Williams and Young 1996a, 1996b)  We focused on seniors given 
that they are the highest per capita users of analgesics (Health Canada 2003), and the size and 
composition of the beneficiary population is relatively stable.  For each drug group and month, 
we measured: (1) the number of defined daily doses (DDDs) dispensed per 100,000 seniors; (2) 
Pharmacare drug expenditure per DDD (equivalently, the average cost per day of therapy); (3) 
Pharmacare drug expenditures per 100,000 seniors; and (4) patient out-of-pocket drug ingredient 
expenditures per 100,000 seniors.  The DDDs were constructed as the total number of mg 
dispensed divided by the World Health Organization estimates (World Health Organization 
2000) of the typical daily maintenance dose (in mg).  Data on the size of the senior population in 
                                                 
1 These include etodolac, phenylbutazone, floctafenine, mefenamic, the SR and enteric coated (other than 650mg) 
forms of ASA, 1 gram SR form of naproxen, as well as the injectable and/or suppository forms of indometacin, 
naproxen, ketoprofen, diclofenac, and piroxicam. 
  6BC were obtained from Statistics Canada (Statistics Canada 2000).  Expenditures data excluded 
dispensing fees and are expressed in Canadian currency.  In March 2004, $1CAN = $0.75US.   
Statistics were produced for individual NSAIDs and also for groups categorized by their 
RP reimbursement status (Unrestricted, First Line Restricted, Second Line Restricted, 
Delisted/Special Authority).  The remaining analgesics were grouped into the following broad 
categories: COX-2s; acetaminophen, codeine, oxycodone and combinations of these drugs; and 
the remaining opiates.   
 
Estimation of policy effects 
For variables (1), (2) and (4), we constructed tables of mean monthly rates during each of 
5 time periods demarcated by the introduction of the 4 major Pharmacare NSAID reimbursement 
policies.  These were: (A) the delisting of sustained release NSAIDs in January 1993; (B) the 
introduction of LCA in April 1994; (C) the application of RP to the NSAID drugs in November 
1995; and (D) the delisting of the Second Line Restricted NSAIDs in November 1996 (most of 
these drugs were relisted in February 1997 but subject to Special Authority prescribing 
restrictions).  The NSAIDs oxyphenylbutazone, diclofenac potassium and ibuprofen (200 and 
400 mg capsules), and the opiates levorphanol, opium tincture, sufentanil and oxymorphone 
were removed from the tables due to their very low prescribing volumes.   
The intended effect of RP is to reduce Pharmacare expenditures by reducing the average 
price paid for NSAID drugs.  Regression models were therefore estimated using monthly data to 
assess how the slope and position of the linear trend in average Pharmacare expenditure per 
DDD of NSAID therapy was affected by the introduction of LCA and RP.  Our identifying 
  7assumption is that the pre-policy intervention trends would have continued into the post-policy 
period had the policies not been implemented.  The estimating model is: 
CostDDDt = β0 + β1 t + β2 LCAt + β3 LCAt×t + β4 RPt + β5 RPt×t + εt       (1) 
where CostDDDt refers to Pharmacare NSAID expenditure per DDD in month t (February 1993 
to June 2001), the LCAt indicator equals 1 in April 1994 and thereafter, and equals 0 otherwise, 
the RPt indicator is equal 1 in November 1995 and thereafter, and equals 0 otherwise.  The β j, 
j=0, …, 5 are unknown parameters estimated using ordinary least squares and εt is the error term.  
Standard errors were estimated using the Newey-West autocorrelation consistent covariance 
matrix (Newey and West 1987) to ensure that hypothesis testing was valid in the presence of up 
to 12-period autocorrelation.  Parameter estimates appear in Appendix 1. 
To estimate total savings from RP, we multiplied the estimated reduction in expenditure 
per DDD by the number of DDDs of all NSAIDs dispensed post-RP (which appeared to be 
unaffected by the introduction of RP).  The savings produced from LCA were estimated in 
analogous fashion. 
Under the terms of the LCA policy, beneficiaries were responsible for any costs in excess 
of the average of the lowest cost (typically generic) drugs in multi-sourced drug categories.  With 
the introduction of RP, non-exempted beneficiaries were also were responsible for any costs in 
excess of the reference price when using Restricted NSAIDs.  We estimated the additional 
average monthly out-of-pocket expenditure per beneficiary and the additional beneficiary 
expenditure per DDD associated with the introduction of RP.  To do so, we estimated linear 
regression models of each of these outcomes as a function of an indicator variable equal to one 
for the months that RP was in effect using observations from the month after introduction of 
LCA (May 1994) to the end of our sample period (June 2001). 




Before RP, the overall volume of NSAIDs dispensed in BC was declining – a trend 
established after the January 1993 delisting of the SR NSAIDs – and RP did not appear to affect 
this decline (Figure 1).  While RP had little effect on the total volume of NSAIDs dispensed, it 
did have a substantial impact on the mix.  In particular, rates of prescribing of Unrestricted 
NSAIDs doubled from 47,417 DDDs dispensed per 100,000 seniors per month during the 19 
months prior to RP to 95,221 DDDs dispensed per 100,000 seniors per month during the 12 
month period immediately after RP (Figure 2, Table 1).  This increase was almost entirely due to 
the increased use of naproxen: Table 1 indicates that mean monthly prescribing rates more than 
tripled between the pre- and post-RP periods.  Rates of ibuprofen use increased by only 25% 
between the same two time periods, while ASA use actually declined 28%.   
Before the introduction of RP, diclofenac and diclofenac-misoprostol were the two most 
commonly prescribed NSAIDs; after Pharmacare restricted reimbursement of these drugs to 
$0.45/day, however, rates of use fell by 45% and 41% respectively.  Not all drugs experienced 
similar declines: rates of use of indomethacin, another commonly used NSAID, declined by only 
9%.  Compared to the 19 months prior to RP, use of the First Line Restricted drugs dropped by 
44% during the year after RP, and dropped a further 10% in the period thereafter.  Use of the 
Second Line Restricted NSAIDs dropped by 48% in the year after RP and dropped an additional 
37% after these drugs were initially delisted and then relisted under the terms of the Special 
  9Authority program.  Finally, use of the NSAIDs that were delisted or placed on special authority 
at various points in time eventually dropped to 35% of the pre-RP rates. 
The introduction of RP was not associated with increased use of acetaminophen, codeine, 
or oxycodone (Figure 1).  The situation is less clear-cut for fentanyl and the other higher potency 
opiates.  While rates of use of these drugs did not increase appreciably in the year after the 
introduction of RP, their use did increase about a year thereafter (i.e. when the Second Line 
Restricted NSAIDs were delisted in November 1996).  Compared to the pre-RP period, mean 
monthly rates of opiates use after November 1996 increased by 53% (Table 1).  Moreover, with 
the gradual decline in NSAIDs use, the opiate share of total analgesic prescribing has increased 
(Figure 1).  Rates of COX-2 NSAID use increased by an average monthly rate of 28% after their 
inclusion on the Pharmacare formulary in September 2000; as of June 2001, roughly 12,000 
defined daily doses were dispensed per 100,000 seniors per month (data not shown). 
 
Pharmacare Expenditures 
During the 19 months prior to the introduction of RP, Pharmacare spent an average of 
$1.32 per DDD (excluding dispensing fees) on seniors taking the Delisted/Special Authority 
NSAIDs, $1.20 per DDD for the Second Line Restricted NSAIDs, $0.87 per DDD for the First 
Line Restricted and $0.16 per DDD on the Unrestricted NSAIDs (Table 2 and Figure 3).  By 
limiting reimbursement of the Restricted drugs to non-exempted seniors to $0.45 per DDD, 
Pharmacare was able to reduce its cost per day by between 20-26%, depending on the Restricted 
drug category, in the first 12 months post-RP.  (Average expenditure did not drop by a greater 
percentage amount because Pharmacare continued to fully reimburse the drug costs of 
exemptees.)  Pharmacare average expenditure per DDD on all NSAIDs eventually dropped by 
  1050%, from $0.80 to $0.40.  Based on regression model (1), we estimate that RP reduced 
(undiscounted) NSAID expenditure by $22.7 million over the 68 month period November 1995 – 
June 2001, with a 95% confidence interval (CI) of $21.1 to $24.3 million.  Annualized savings 
are $4.0 million per year (95% CI: $3.7 to $4.3 million), or 44% of the $9.1 million Pharmacare 
spent on NSAIDs for seniors in the 12 months prior to RP.  These savings were not offset by 
additional expenditures on other analgesic drugs (Figure 5): While there was a gradual increase 
in opiate use (Figure 1), there was an offsetting decline in Pharmacare’s reimbursement rates for 
these drugs (Figure 4).  Budgetary savings produced by LCA over the 87 month period April 
1994 – June 2001 were estimated to be $7.5 million (95% CI: $4.1 to $10.9 million).  
Annualized savings were $1.0 million (95% CI: $0.6 to 1.5 million), or 10% of the $10 million 
Pharmacare spent on NSAIDs for seniors in the year prior to LCA. 
 
Patient Expenditures 
Out-of-pocket NSAID expenditures across all seniors increased by an average of 
$798,000 annually after the introduction of RP (95% CI: $647,000 to $948,000); this represents 
about 20% of annual Pharmacare savings on NSAIDs (Figure 6).  Average additional cost per 
senior was modest.  During the LCA period (April 1994 to October 1995), each senior paid on 
average $0.02 per month to substitute brandname for generic NSAID drugs.  After RP, each 
senior spent an additional $0.13 per month for Restricted NSAID drugs (95% CI: $0.10 to 
$0.15).  Since not all seniors used Restricted NSAIDs post-policy, however, the cost per user 
was likely much higher.  These figures also exclude out-of-pocket costs for those seniors who 
did not receive a Special Authority exemption for Second Line Restricted drugs used after 
  11November 1996.  (As Pharmacare did not pay for any portion of these drugs, data on their use 




The Reference Pricing policy reduced NSAID expenditure on its senior beneficiaries by 
about $4 million annually during the 5 years following its introduction.  The policy did so by 
reducing average Pharmacare expenditure per day of NSAID therapy by about half; the total 
volume of NSAIDs dispensed was unaffected.  These savings accrued despite liberal exemption 
criteria and the opportunity for physicians to prescribe higher potency analgesics that were not 
subject to reimbursement restriction.  Similar relative expenditure reductions were realized after 
the Medicaid programs of Georgia and Tennessee implemented prior authorization programs for 
various higher-cost NSAIDs (Kotzan et al. 1993;  Smalley et al. 1995).  However, in both 
programs some of the expenditure reduction was due to decreased NSAID use.  Application of 
the generic substitution policy in BC produced annualized savings of $1 million, or roughly one 
quarter those realized by RP.  RP was able to achieve larger savings by exploiting substantial 
price differences between different NSAIDs; GS could only exploit price differences that existed 
between the different brands of multi-sourced NSAIDs. 
GS and RP were also applied to Pharmacare’s other beneficiary groups – residents of 
long-term care facilities, social assistance recipients and households whose drug costs exceed an 
income-contingent deductible.  In 1999, Pharmacare drug expenditures on these groups were 
sizeable – about 86% of Pharmacare expenditures on seniors (British Columbia Ministry of 
  12Health Services 2001).  Given that per capita analgesic use is likely lower among these groups, 
however, RP probably generated less than proportionate budgetary savings. 
Pharmacare has applied RP to several other therapeutic groups and analysts have now 
estimated the savings accruing to Pharmacare’s seniors’ drug program for each of them.  The 
present analysis finds savings for NSAIDs to be $4 million annually.  Marshall et al. (2002) 
found that the application of RP to the H2 blockers in October 1995 and the concurrent 
application of Special Authority to the proton pump inhibitors saved Pharmacare between $7.3 to 
$8.7 million annually, depending on the estimation method chosen.  Grootendorst et al. (2001b) 
estimated that the application of RP to the 3 groups of cardiac drugs – the ACE inhibitors and 
Calcium Channel Blockers (both targeted by RP in January 1997) and nitrates (November 1995) 
– saved Pharmacare about $7.8 million annually.  Hence combined savings are between $19.1 
and $20.5 million annually; this does not include any savings on Pharmacare subsidies for non-
senior beneficiaries.  
While the total volume of NSAIDs dispensed did not change appreciably after RP, the 
mix of NSAIDs dispensed did.  In particular, the use of the lower cost, fully reimbursed NSAIDs 
increased from 23% to 58% of total NSAID use.   This was due primarily to the increased use of 
naproxen.  The use of First Line Restricted drugs – especially diclofenac, diclofenac-
misoprostol, enteric-coated and SR naproxen, and ketoprofen – dropped after the implementation 
of RP.  When RP was introduced, acetaminophen was placed on the formulary in recognition of 
its importance in treating mild to moderate arthritis.  However, it was not commonly prescribed.  
There was a moderate increase in rates of opiate use 2 years after RP was introduced; it is 
unclear if this was attributable to RP.   
  13Savings generated from RP need to be compared to its potential costs.  First, switching 
between NSAIDS to comply with the policy may have worsened symptoms.  While we did not 
have data on patient health outcomes and individual patients commonly report better efficacy 
and/or tolerability with particular NSAIDs (Langman et al. 2001; Walker, Chan, and Yood 
1992), we note that there is no consistent evidence of clinically significant differences in the anti-
inflammatory and analgesic effect of the numerous different NSAIDs (Holbrook 2001; Brooks 
and Day 1991).  Retrospective analyses of observational data have suggested a hierarchy among 
conventional NSAIDs in their potential for gastrointestinal injury, but these differences can be 
attributed to variations in effective dose and channeling bias (Rodriguez 1998; Henry 1996).  
Others have studied the effects of prior authorization programs targeting higher cost NSAIDs on 
the health related quality of life (Momani, Madhavan, and Nau 2002) and medical services use 
(Kotzan et al. 1993;  Smalley et al. 1995) of chronic NSAID users enrolled in various US state 
Medicaid programs.  None of these studies detected any deleterious effects among those who 
were not given Medicaid subsidies for the higher cost NSAIDs. 
Second, patient expenditures increased by about 20% of Pharmacare savings, and likely 
more due to spending on delisted drugs and spending by patients who were denied special 
authority exemptions for the COX-2 NSAIDs and other analgesics.  Finally, RP may have 
generated administrative costs.  Patients taking Restricted NSAIDs likely consulted their 
physician about treatment options (e.g., switching to a fully reimbursed drug, applying for an 
exemption or paying out-of-pocket costs); those who switched were likely monitored.  
Physicians and especially pharmacists were observed to spend considerable uncompensated time 
explaining the RP policy to patients, especially when RP was first introduced (Kent 2000; 
Mullett and Coughlan 1998; Woollard 1996).  
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  17Table 1  Average monthly number of defined daily doses dispensed per 100,000 seniors, by 




Unrestricted asa ect 650mg tab 42,922 219 31,408 160 19,622 100 14,071 72 7,779 40
ibuprofen tab 14,835 170 11,721 134 8,737 100 10,906 125 11,221 128
naproxen tab 27,966 147 26,693 140 19,058 100 70,244 369 68,206 358
Subtotal 85,723 181 69,822 147 47,417 100 95,221 201 87,206 184
First Line Restricted diclofenac 81,432 214 54,985 145 37,995 100 20,328 54 16,968 45
diclofenac/misoprostol 12,725 48 26,248 100 15,552 59 15,994 61
diflunisal 3,729 253 2,120 144 1,474 100 692 47 446 30
fenoprofen 852 220 541 140 387 100 199 51 128 33
flurbiprofen 5,611 224 3,805 152 2,501 100 1,207 48 838 34
indometacin 18,508 160 13,622 118 11,555 100 10,545 91 9,636 83
ketoprofen 27,252 277 16,185 165 9,836 100 5,580 57 3,241 33
naproxen ect & sr 11,186 53 11,956 57 20,982 100 7,772 37 4,308 21
salsalate 288 100 276 96 138 48
Subtotal 148,570 134 115,939 104 111,266 100 62,151 56 51,697 46
Second Line Restricted sulindac 8,492 203 5,762 138 4,189 100 2,048 49 598 14
nabumetone 5,749 100 5,714 99 2,146 37
piroxicam cap 12,006 193 8,830 142 6,215 100 3,034 49 672 11
tenoxicam 5,251 54 9,431 97 9,724 100 3,259 34 660 7
tiaprofenic acid 15,404 160 12,761 133 9,613 100 4,445 46 993 10
tolmetin 3,119 206 2,183 144 1,514 100 882 58 424 28
Subtotal 44,272 120 38,967 105 37,004 100 19,382 52 5,493 15
Delisted/Special Auth. ketorolac tromethamine inj 17 100 16 94 17 100 8 47 8 47
ketorolac tromethamine tab 6,243 170 4,701 128 3,668 100 1,623 44 48 1
etodolac 28 100 132 471 41 146
indometacin sup 2,686 172 2,154 138 1,565 100 1,362 87 1,003 64
mefenamic 206 147 166 119 140 100 118 84 96 69
naproxen sup/inj 1,256 196 905 141 640 100 658 103 504 79
naproxen 1 gram sr 4,242 140 4,288 142 3,025 100 2,967 98 1,396 46
phenylbutazone 276 223 178 144 124 100 98 79 74 60
ketoprofen sup 1,172 234 801 160 500 100 316 63 177 35
diclofenac sup 1,863 137 1,650 121 1,361 100 1,184 87 1,038 76
piroxicam sup 704 146 550 114 482 100 324 67 47 10
floctafenine 1,150 203 969 171 566 100 348 61 185 33
asa ect tab, sr tab/cap 3,862 249 2,446 158 1,551 100 1,195 77 209 13
Subtotal 23,677 173 18,824 138 13,667 100 10,333 76 4,826 35
All NSAIDs 302,242 144 243,552 116 209,354 100 187,087 89 149,222 71
COX-2 NSAIDS 7,199
ACETAMINOPHEN & acetaminophen 3,012 4,472
MILD OPIATES codeine 1,183 115 1,027 100 1,032 100 1,105 107 1,931 187
codeine/acetaminophen 71,455 101 78,555 111 70,694 100 70,277 99 70,937 100
codeine/asa 7,476 159 5,883 125 4,692 100 4,234 90 3,469 74
oxycodone/acetaminophen 1,565 109 1,520 106 1,436 100 1,643 114 2,327 162
All Acetam./Mild Opiates 81,679 105 86,985 112 77,854 100 80,271 103 83,136 107
OPIATES fentanyl 7,330 42 20,558 117 17,636 100 17,924 102 30,189 171
hydromorphone 4,746 88 5,467 101 5,414 100 6,360 117 13,130 243
meperidine 361 98 358 98 367 100 363 99 412 112
morphine 6,129 82 7,339 98 7,499 100 8,881 118 9,795 131
propoxyphene 5,009 137 4,250 116 3,662 100 3,405 93 325 9
anileridine 471 97 489 101 485 100 540 111 552 114
pentazocine 923 181 695 137 509 100 490 96 159 31
All Opiates 24,969 70 39,156 110 35,572 100 37,963 107 54,562 153
Delistings
Nov 96 - Jun 01
Historical
Nov 89 - Dec 92
SR Delisted
Jan 93 - Mar 94
LCA RP NSAIDs
Apr 94 - Oct 95 Nov 95 - Oct 96
Time Period
 
Notes: the bolded values indicate period-specific average monthly rates relative to rates in the 
LCA period. 




Unrestricted asa ect 650mg tab 0.23 173 0.22 167 0.13 100 0.12 91 0.12 91
ibuprofen tab 0.25 217 0.20 173 0.11 100 0.11 96 0.11 93
naproxen tab 0.32 143 0.27 122 0.22 100 0.22 97 0.21 95
Subtotal 0.26 158 0.23 143 0.16 100 0.19 115 0.19 115
First Line Restricted diclofenac 1.19 140 1.05 123 0.85 100 0.63 74 0.59 69
diclofenac/misoprostol 1.24 101 1.23 100 1.01 82 0.90 73
diflunisal 1.04 121 1.12 131 0.85 100 0.64 75 0.64 75
fenoprofen 1.12 95 1.20 101 1.18 100 0.89 75 0.95 80
flurbiprofen 1.31 155 1.23 146 0.84 100 0.63 75 0.61 72
indometacin 0.89 206 0.52 121 0.43 100 0.40 94 0.35 81
ketoprofen 1.05 189 0.92 167 0.55 100 0.46 84 0.42 75
naproxen ect & sr 0.94 111 0.84 99 0.85 100 0.59 70 0.49 57
salsalate 1.44 100 1.24 86 1.14 79
Subtotal 1.11 127 0.98 112 0.87 100 0.67 77 0.62 72
Second Line Restricted sulindac 1.27 121 1.27 121 1.04 100 0.83 79 1.00 96
nabumetone 1.48 100 1.24 84 1.29 87
piroxicam cap 1.03 128 1.01 126 0.81 100 0.64 79 0.73 90
tenoxicam 1.36 102 1.36 102 1.34 100 1.07 80 1.09 82
tiaprofenic acid 1.43 115 1.46 118 1.24 100 0.80 65 0.94 76
tolmetin 1.03 105 1.10 112 0.98 100 0.79 80 0.90 92
Subtotal 1.25 105 1.29 108 1.20 100 0.95 80 1.07 89
Delisted/Special Auth. ketorolac tromethamine inj 5.64 116 4.94 102 4.84 100 4.62 96 4.83 100
ketorolac tromethamine tab 1.87 97 1.90 99 1.93 100 0.93 48 1.34 70
etodolac 1.01 100 0.97 97 0.85 84
indometacin sup 1.46 105 1.58 114 1.39 100 1.23 89 1.04 75
mefenamic 2.02 83 2.40 99 2.43 100 2.39 98 1.65 68
naproxen sup/inj 1.36 115 1.46 123 1.19 100 1.00 84 0.92 77
naproxen 1 gram sr 0.93 142 0.89 135 0.66 100 0.64 97 0.64 98
phenylbutazone 0.52 737 0.35 501 0.07 100 0.05 77 0.06 82
ketoprofen sup 2.30 114 2.40 119 2.01 100 1.86 93 1.59 79
diclofenac sup 1.45 93 1.54 99 1.56 100 1.40 90 1.14 73
piroxicam sup 1.68 91 1.86 100 1.85 100 1.76 95 1.41 76
floctafenine 1.66 94 1.74 99 1.76 100 1.73 99 1.71 98
asa ect tab, sr tab/cap 0.38 104 0.36 98 0.36 100 0.39 108 0.38 104
Subtotal 1.35 102 1.38 105 1.32 100 0.98 74 0.96 73
All NSAIDs 0.91 114 0.85 106 0.80 100 0.47 59 0.40 50
COX-2 NSAIDS 0.98
ACETAMINOPHEN & acetaminophen 0.14 0.11
MILD OPIATES codeine 0.45 104 0.48 111 0.43 100 0.38 87 0.36 84
codeine/acetaminophen 0.17 147 0.18 149 0.12 100 0.12 98 0.13 110
codeine/asa 0.78 97 0.90 113 0.80 100 0.83 104 0.81 101
oxycodone/acetaminophen 2.64 254 3.10 298 1.04 100 0.87 84 0.86 82
All Acetam./Mild Opiates 0.28 155 0.28 155 0.18 100 0.17 96 0.18 102
OPIATES fentanyl 0.21 102 0.20 99 0.21 100 0.20 97 0.19 93
hydromorphone 0.47 145 0.39 122 0.32 100 0.33 104 0.39 123
meperidine 1.47 96 1.55 102 1.53 100 1.48 97 1.44 94
morphine 2.85 94 3.04 101 3.02 100 2.89 96 2.52 83
propoxyphene 0.83 97 0.87 102 0.86 100 0.84 98 0.84 98
anileridine 4.45 97 4.60 100 4.58 100 4.45 97 4.31 94
pentazocine 1.43 93 1.53 100 1.53 100 1.49 97 1.44 94
All Opiates 1.17 119 0.93 95 0.98 100 1.00 102 0.72 73
Historical SR Delisted LCA RP NSAIDs
Time Period
Delistings
Nov 89 - Dec 92 Jan 93 - Mar 94 Apr 94 - Oct 95 Nov 95 - Oct 96 Nov 96 - Jun 01
 
Notes: the bolded values indicate period-specific average monthly rates relative to rates in the 
LCA period. 
  19Table 3  Average monthly beneficiary out-of-pocket expenditure per 100,000 seniors, by 




Unrestricted asa ect 650mg tab 0 0 0 0 66 100 127 192 91 138
ibuprofen tab 0 0 0 0 22 100 80 364 93 423
naproxen tab 0 0 0 0 32 100 286 894 463 1,447
Subtotal 0 0 0 0 120 100 493 411 647 539
First Line Restricted diclofenac 0 0 0 0 342 100 5,449 1,593 4,918 1,438
diclofenac/misoprostol 0 0 0 170 100 3,401 2,001 4,693 2,761
diflunisal 0 0 0 0 19 100 155 816 96 505
fenoprofen 0 0 0 0 4 100 58 1,450 26 650
flurbiprofen 0 0 0 0 30 100 286 953 234 780
indometacin 0 0 0 0 132 100 905 686 522 395
ketoprofen 0 0 0 0 308 100 1,014 329 623 202
naproxen ect & sr 0 0 0 0 141 100 1,965 1,394 1,517 1,076
salsalate 0 0 0 6 100 59 983 42 700
Subtotal 0 0 0 0 1,152 100 13,292 1,154 12,671 1,100
Second Line Restricted sulindac 0 0 0 0 31 100 528 1,703 20 65
nabumetone 00 105 100 1,424 1,356 128 122
piroxicam cap 0 0 0 0 48 100 534 1,113 23 48
tenoxicam 0 0 0 0 60 100 732 1,220 39 65
tiaprofenic acid 0 0 0 0 252 100 1,119 444 47 19
tolmetin 0 0 0 0 41 100 135 329 12 29
Subtotal 0 0 0 0 537 100 4,472 833 269 50
Delisted/Special Auth. ketorolac tromethamine inj 0 0 0 1 2
ketorolac tromethamine tab 0 0 0 0 29 100 1,643 5,666 27 93
etodolac 0 0 0
indometacin sup 0 0 0 0 23 100 118 513 59 257
mefenamic 0 0 0 0 1 100 3 300 8 800
naproxen sup/inj 0 0 0 0 24 100 28 117 18 75
naproxen 1 gram sr 0 0 0 0 9 100 29 322 14 156
phenylbutazone 0 0 0 0 0
ketoprofen sup 0 0 0 0 20 100 26 130 15 75
diclofenac sup 0 0 0 0 5 100 91 1,820 89 1,780
piroxicam sup 0 0 0 14 2
floctafenine 0 0 0 0 3 100 10 333 8 267
asa ect tab, sr tab/cap 0 0 0 0 3 100 11 367 9 300
Subtotal 0 0 0 0 117 100 1,974 1,687 251 215
All NSAIDs 0 0 0 0 1,926 100 20,231 1,050 13,838 718
COX-2 NSAIDS 74
ACETAMINOPHEN & acetaminophen 0 0 0 145 207
MILD OPIATES codeine 0 0 0 0 4 100 31 775 39 975
codeine/acetaminophen 0 0 0 0 133 100 225 169 452 340
codeine/asa 0 0 0 0 83 100 156 188 285 343
oxycodone/acetaminophen 0 0 0 0 151 100 523 346 521 345
All Acetam./Mild Opiates 0 0 0 0 371 100 1,080 291 1,504 405
OPIATES fentanyl 0 0 0 0 2 100 0 0 95 4,750
hydromorphone 0 0 0 0 23 100 60 261 122 530
meperidine 0 0 0 0 2 100 9 450 22 1,100
morphine 0 0 0 0 296 100 748 253 1,061 358
propoxyphene 0 0 0 0 17 100 45 265 9 53
anileridine 0 0 0 0 18 100 48 267 81 450
pentazocine 0 0 0 0 2 100 104 5,200 4 200
All Opiates 0 0 0 0 360 100 1,014 282 1,394 387
Delistings
Nov 89 - Dec 92 Jan 93 - Mar 94 Apr 94 - Oct 95 Nov 95 - Oct 96 Nov 96 - Jun 01
Historical SR Delisted LCA RP NSAIDs
Time Period
Notes: the bolded values indicate period-specific average monthly rates relative to rates in the 
LCA period.
  20Figure 1  Defined daily doses of analgesics dispensed per 100,000 seniors, by analgesic category and month 
 
Notes: We fit a moving average trend line through the data points. 
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  26Appendix 1  Parameter estimates 
 
outcome: Pharmacare reimbursement per defined daily dose NSAID therapy 
estimation period: February 1993 - June 2001 (n=101) 
 
Covariate coefficient t-ratio p-value
t  0.002 3.97 <0.001
LCA  0.368 1.74 0.086
LCA×t  -0.001 -2.01 0.048
RP  0.658 2.52 0.013
RP×t  -0.002 -4.20 <0.001
Constant  0.029 0.14 0.886
 
 
outcome: beneficiary reimbursement per defined daily dose NSAID therapy 
estimation period: May 1994 – June 2001 (n=86)  
 
Covariate coefficient t-ratio p-value
RP  0.130 9.34 <0.001
Constant  0.020 1.96 0.053
 
 
outcome: beneficiary expenditure on NSAIDs  
estimation period: May 1994 - June 2001 (n=86)  
 
Covariate coefficient t-ratio p-value
RP  66,461.200 10.54 <0.001
Constant  9,488.796 1.95 0.054
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